Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study

Journal of Infectious Diseases

Volumn 213, Issue 10, 2016, Pages 1562-1572

  Sirivichayakul, Chukiat ^a   Barranco Santana, Elizabeth A ^c   Esquilin Rivera, Incrossed D Signs ^d   Oh, Helen M L ^g   Raanan, Marsha ^j   Sariol, Carlos A ^d,e,f   Shek, Lynette P ^h   Simasathien, Sriluck ^b   Smith, Mary Kathryn ^j   Velez, Ivan Dario ^l   Wallace, Derek ⁱ   Gordon, Gilad S ^k   Stinchcomb, Dan T ^j  

^a MAHIDOL UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d Department of Pediatrics ^*  (Puerto Rico)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f Latin Clinical Trial Center   (Puerto Rico)

^g CHANGI GENERAL HOSPITAL   (Singapore)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ Takeda Vaccines Pte Ltd   (Singapore)

^j Takeda Vaccines   (United States)

^k Orra Group LLC   (United States)

^l UNIVERSIDAD DE ANTIOQUIA   (Colombia)

more..

Author keywords

Adults; Children; Immunogenicity; Live attenuated tetravalent dengue vaccine; Safety

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; ALLERGIC RHINITIS; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; COLOMBIA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; EYE PAIN; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; JOINT STIFFNESS; KAPOSI VARICELLIFORM ERUPTION; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONHUMAN; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; RASH; SINGAPORE; THAILAND; VOMITING; ADOLESCENT; CLINICAL TRIAL; DENGUE VIRUS; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; SAFETY; STANDARDS; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COLOMBIA; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PUERTO RICO; SAFETY; SINGAPORE; THAILAND; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84969975038     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv762     Document Type: Article

References (27)

1. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control, 2009. http://books.google.com.sg/books?hl=en&lr=&id= dlc0YSIyGYwC&oi=fnd&pg=PP2&dq=dengue+anticoagulant+treatment&ots= OMuWEB5Im7&sig=-hMVWYfaCifFx-IoAtNWy3SJBw#v=onepage&q=den gue%20anticoagulant%treatment&f=false. Accessed 5 May 2015.
2. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med 2012; 366: 1423-32.
3. WHO. Dengue and severe dengue: fact sheet No. 117, 2014. http://www.who.int/ mediacentre/factsheets/fs117/en/. Accessed 25 May 2015.
4. Halstead SB. Dengue. Lancet 2007; 370:1644-52.
5. Trung DT, Thao le TT, Dung NM, et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis 2012; 6:e1679.
6. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 2004; 9:1022-9.
7. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8:S7-16.
8. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
9. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis 2002; 2:33-42.
10. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360:1243-5.
11. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
12. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. BMC Public Health 2015; 15:250.
13. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013; 158:1445-59.
14. Slifka MK. Vaccine-mediated immunity against dengue and the potential for longterm protection against disease. Front Immunol 2014; 5:195.
15. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
16. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011; 24:442-50.
17. Chanthavanich P, Luxemburger C, Sirivichayakul C, et al. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 2006; 75:26-8.
18. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003; 77:11436-47.
19. Osorio JE, Brewoo JN, Silengo SJ, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011; 84:978-87.
20. Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14:830-8.
21. George SL,Wong MA, Dube TJT, et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J Infect Dis 2015; 212:1032-41.
22. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2:60-7.
23. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011; 85:724-31.
24. Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013; 31:4501-7.
25. da Costa VG, Marques-Silva AC, Floriano VG, Moreli ML. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. Vaccine 2014; 32:4885-92.
26. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65.
27. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23.